💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains insteadUnlock them all

PRESS DIGEST- New York Times business news - Oct 22

Published 2015-10-22, 01:09 a/m
© Reuters.  PRESS DIGEST- New York Times business news - Oct 22
BHC
-

Oct 22 (Reuters) - The following are the top stories on the
New York Times business pages. Reuters has not verified these
stories and does not vouch for their accuracy.

- The U.S. Treasury on Wednesday urged Congress to help
debt-stricken Puerto Rico, saying the U.S. commonwealth needs
the ability to file for bankruptcy protection, changes to
Medicaid funding and access to the Earned Income Tax Credit.

- A report from Citron Research, which all but called
Valeant VRX.TO the pharmaceutical equivalent of Enron, set in
motion a tidal wave of selling on Wednesday. At one point,
shares of Valeant were down as much as 40 percent.

- In an important breakthrough for Chinese industry and
global influence, the British and Chinese governments agreed on
Wednesday to give China a substantial stake in the British
nuclear industry, both as an investor and as a contractor.

- Buyout firm Kohlberg Kravis Roberts is taking part in a
$50 million investment led by KKR & Co KKR.N in Cohera
Medical, a Pittsburgh-based start-up focused on creating
adhesives that can replace surgical sutures. As part of the
investment, Ali Satvat, a director at KKR who led the
transaction, will join Cohera's board.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.